December 2020

It’s been 40 years since HIV rocked the pharma industry, but while treatments have been identified to help patient­­­s manage the virus, a HIV vaccine has remained elusive. To find out why, we explore the current state of HIV research and the challenges that stand in the way of vaccine development. Elsewhere in vaccines, we take a look at the AI software Opyl, which could help researchers predict the success of Covid-19 vaccine candidates.

Also in this issue, we investigate cancer treatment disparity in Europe, examine the potential of a drug tracking app that gives patients a platform to openly review their medications, and speak to Novo Ventures about investing in niche drug development in the middle of a pandemic.

Plus, after Covid-19 vaccine developers vowed not to file for approval without first demonstrating positive Phase III trial results, we find out what makes Phase III clinical trials so important, learn about plant-based medicine production and explore ways that air freight hubs worldwide are preparing for an influx of in-demand Covid-19 treatments and vaccines.

EDITORIAL

Editor | Eloise McLennan

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Natalie Healey, Abi Millar, Chloe Kent
Magazine Designer | Marzia Del Gaone

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Filipe Costa, Martina Labaiova
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

For media partnership enquiries please contact: Susanne Hauner

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2020 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Covid-19 and the anti-vax movementGo to article: In this issueGo to article: ContentsGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Mettler Toledo Company InsightGo to article: Mettler ToledoGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: PuroliteGo to article: VEGA AustraliaGo to article: Gerteis Company Insight Go to article: GerteisGo to article: CommentGo to article: US election: Trump and Biden's priorities in the Covid-19 responseGo to article: Covid-19 disruption to trials declines, but recruitment is slowGo to article: Covid-19 vaccine developments across the globeGo to article: Eli Lilly and Regeneron’s EUA bids trigger concerns over available Covid-19 dataGo to article: AstraZeneca’s quick Covid-19 vaccine trial restart splits opinionGo to article: Q&A: Atomwise’s journey from discoverer to developerGo to article: Pfeiffer VacuumGo to article: Koehler eClinicalGo to article: Phoenix Company Insight Go to article: PhoenixGo to article: In DepthGo to article: How to combat vaccine hesitancy in the age of Covid-19Go to article: How Covid-19 has put clinical research’s diversity problem in the spotlight Go to article: No need for animal testing: improving vaccine research with GenoskinGo to article: Gout: drug development for an age-old diseaseGo to article: Treating chronic primary pain in the UKGo to article: Breast cancer breakthrough: could a new therapy silence stubborn TNBC?Go to article: Is quantum computing pharma's next big disruptor?Go to article: MimotopesGo to article: OptelGo to article: Solvias Company Insight Go to article: SolviasGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: IWA Consulting Company Insight Go to article: IWA consultingGo to article: Nipro pharmapackagingGo to article: SwiftpakGo to article: EventsGo to article: Next issue